2022 Fiscal Year Annual Research Report
Precision-Targeted Nanotherapy for Ischemic Stroke and Related CNS Disorders
| Project/Area Number |
20K16428
|
|---|
| Research Institution | Toyo University |
|---|
Principal Investigator |
モハメッド シェイク 東洋大学, バイオ・ナノエレクトロニクス研究センター, 研究助手 (50708609)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | Nano DDS / Ischemic Stroke / Central Nervous System / Blood Brain Barrier / Neuronal Degeneration |
|---|
| Outline of Annual Research Achievements |
Outline: The project entitled ‘Precision-Targeted Nanotherapy for Ischemic Stroke and Related CNS Disorders’ was designed to make neurotrophins, a clinical reality for patients with neuronal degeneration and physical trauma, particularly ischemic stroke. For this purpose, specific peptide targeted hybrid solid lipid nanoformulations (HSLNs) encapsulating specific neurotrophic factors with ability to trespass the blood brain barrier (BBB) and alleviate neuronal degeneration were utilized with promising results.
Summary: The nanoformulations had excellent in vivo biocompatibility when tested on C57BL/6J mice. Successful MCAO models were established and the nanoformulations tested on them. The nanoformulations tested were HSLNs loaded with NGF & BDNF and were either non-targeted or RDP/RMP-7 targeted. For targeting potential investigations ICG dye was encapsulated instead of the neurotrophins. Excellent results were achieved in the RDP targeted HSLNs with increased accumulation, determined by in vivo/ex vivo imaging, in the ischemic region of the brain. This was reflected in the therapeutic investigations as well with majority of the ischemia induced-RDP/BDNF HSLN treated mice showing nil to highly reduced ischemic zone. Overall, the research was a great success.
|
